CHCWM – Cancer & Hematology Centers of West Michigan

XMT-1536-2A (Mersana)

Description:  An Open-Label, Multicenter, Dose Escalation and Expansion Modular, Umbrella Master Study of Upifitamab Rilsodotin In Combination with Other Agents in Participants with High-Grade Serous Ovarian Cancer (Upgrade)

Mechanism of Action:  Antibody Drug Conjugate targeting NaPi2b (sodium dependent phosphate transporter) present on apical membranes of epithelial cells along with Carboplatin

Target Patient Population:   Platinum sensitive Ovarian Cancer

Study Design:  Drug is given IV every 4 week